


FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GENENT.066AAPPLICATION NO.
09/921,161APPLICANT
Peter RalphFILING DATE
August 1, 2001GROUP
1645INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)



RECEIVED

OCT 12 2001

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
jr	1.	4,968,603	11.6.90	Slamon et al.	X	X	
	2.	5,480,792	1-2-96	Buechler et al.			
	3.	5,501,983	3-26-96	Lilja et al.			
	4.	5,821,337	10-13-98	Carter et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL		
jr	5.	Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-erb B2/neu and c-erbB" <u>Br. J. Cancer</u> 57:358-363 (1988)
	6.	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 ^{HER2} Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14:737-744 (1996)
	7.	Bastiaens and Squire, "Fluorescence lifetime imaging microscopy: spatial resolution of biochemical processes in the cell" <u>Trends Cells Biol.</u> 9:48-52 (1999)
	8.	Borst et al., "Oncogene Alterations in Endometrial Carcinoma" <u>Gynecol. Oncol.</u> 38:364 (1990)
	9.	Carter et al., "Humanization of an anti-p185 HER2 antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89: 4285 (1992)
	10.	Cohen et al., "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185 ^{neu}) in normal and transformed tissues of the digestive tract" <u>Oncogene</u> , 4:81-88 (1989)
	11.	Fehm et al., "The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer" <u>Oncology</u> 55: 33-38 (1998)
	12.	Fukushigi et al., "Localization of a Novel v-erbB-Related Gene, c-erbB-2, on Human Chromosome 17 and Its Amplification in a Gastric Cancer Cell Line" <u>Mol Cell Biol.</u> 6:955-958 (1986)
	13.	Geurin et al., "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" <u>Oncogene Res.</u> 3:21-31 (1988)
	14.	Gu et al., "Overexpression of her-2/neu in human prostate cancer and benign hyoerplasia" <u>Cancer Lett.</u> 99:185-9 (1996)

EXAMINER

DATE CONSIDERED

9/2/04

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GENENT.066AAPPLICATION NO.
09/921,161INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Peter RalphFILING DATE
August 1, 2001GROUP
1645

RECEIVED

OCT 12 2001

TECH CENTER 1600/2900

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)


- | | | |
|-----|---|---|
| 15. | Hudziak et al., "p185 ^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Mol. Cell. Biol.</u> 9(3):1165-1172 (1989) | ✓ |
| 16. | Kern et al., "p185 ^{neu} Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" <u>Cancer Res.</u> 50:5184 (1990) | ✓ |
| 17. | King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinome" <u>Science</u> , 229:974 (1985) | ✓ |
| 18. | Kobayashi et al. "Detectuib of Microfilarial Antigen in Circulating Immune Complex from Sera of Wuchereria Bancrofti-infected individuals" <u>Am. J. Trop. Med. Hyg.</u> 57: 200-204 (1997) | ✓ |
| 19. | Park et al., "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas" <u>Cancer Res.</u> , 49:6605 (1989) | ✓ |
| 20. | Ross et al. "Prognostic Significance of HER-2/neu Gene" <u>Cancer</u> 79:2162-70 (1997) | ✓ |
| 21. | Ross et al., " HER-2/neu Gene Amplification Status in Prostate Cancer by Fluorescence in Situ Hybridization" <u>Hum. Pathol.</u> 28:827-33 (1997) | ✓ |
| 22. | Sadasivan et al., "Overexpression of HER-2/neu May be an Indicator of Poor Prognosis in Prostate Cancer" <u>J. Urol.</u> 150:126-31 (1993) | ✓ |
| 23. | Schmerr et al., "Improvements in a competition assay to detect scrapie prion protein by capillary electrophoresis" <u>J. Chromatogr. B. Biomed. Appl.</u> 681: 29-35 (1996) | ✓ |
| 24. | Schüpbach et al., "Heat-mediated immune complex dissociation and enzyme-linked immunosorbent assay signal amplification render p24 antigen detection in plasma as sensitive as HIV-1 RNA detection by polymerase chain reaction" <u>J. Infect. Dis.</u> 170: 318-324 (1994) | ✓ |
| 25. | Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> , 235:177-182 (1987) | ✓ |
| 26. | Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> , 244:707-712 (1989) | ✓ |
| 27. | Steindl et al., "A simple and robust method for the complete dissociation of HIV-1 p24 and other antigens from immune complexes in serum and plasma samples" <u>J. Immunol. Methods</u> 217: 143-151 (1998) | ✓ |
| 28. | Weiner et al., "Expression of the neu Gene-encoded Protein (P185 ^{neu}) in Human Non-Small Cell Carcinomas of the Lung" <u>Cancer Res.</u> , 50:421-425 (1990) | ✓ |
| 29. | Williams et al., "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas" <u>Pathobiology</u> 59:46-52 (1991) | ✓ |
| 30. | Yamauchi et al., "Prediction of Response to Antiestrogen Therapy in Advanced Breast Cancer Patients by Pretreatment Circulating Levels of Extracellular Dpomain of the HER-2/c-neu Portein" <u>J. Clin. Oncol.</u> 15: 2518-2525 (1997) | ✓ |
| 31. | Yokota et al., "Amplification of c-erbB-2 Oncogene in Human Adenocarcinomas in Vivo" <u>Lancet</u> : 1:765-767 (1986) | ✓ |
| 32. | Yonemura et al., "Evaluation of Immunoreactivity for erbB-2 Portein as a Marker of Poor Short Term Prognosis in Gastric Cancer" <u>Cancer Res.</u> , 51:1034 (1991) | ✓ |


EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

<p>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>OIPE INFORMATION DISCLOSURE STATEMENT OCT 09 2009 BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) PATENT & TRADEMARK OFFICE</p>	ATTY. DOCKET NO. GENENT.066A	APPLICATION NO. 09/921,161
	APPLICANT Peter Ralph	
	FILING DATE August 1, 2001	GROUP 1645

EXAMINER INITIAL 	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	33. <u>Zhou et al., "Amplification and Expression of the c-erb B-2/neu Proto-Oncogene in Human Bladder Cancer" <u>Mol. Carcinog.</u>, 3:354-357 (1990)</u>

EXAMINER 	DATE CONSIDERED <u>7/2/04</u>
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	